Published in J Immunol on November 14, 2012
Once a Treg, always a Treg? Immunol Rev (2014) 1.27
Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol (2013) 1.15
Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol (2013) 1.04
Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol (2013) 1.03
Thymic versus induced regulatory T cells - who regulates the regulators? Front Immunol (2013) 0.98
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
Interleukin-35 Limits Anti-Tumor Immunity. Immunity (2016) 0.93
Trans-vivo delayed type hypersensitivity assay for antigen specific regulation. J Vis Exp (2013) 0.89
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia (2014) 0.89
HY immune tolerance is common in women without male offspring. PLoS One (2014) 0.88
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86
Interleukin-35: Expanding Its Job Profile. J Interferon Cytokine Res (2015) 0.83
Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis. Chin J Cancer Res (2013) 0.81
Effect of Regulatory T Cells on Promoting Apoptosis of T Lymphocyte and Its Regulatory Mechanism in Sepsis. J Interferon Cytokine Res (2015) 0.81
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol (2013) 0.79
Patterns of Immune Regulation in Rhesus Macaque and Human Families. Transplant Direct (2015) 0.78
Interactions between Autophagy and Inhibitory Cytokines. Int J Biol Sci (2016) 0.78
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology (2016) 0.76
Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis. Am J Transl Res (2016) 0.76
Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer (2013) 0.75
Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade. Transplant Direct (2016) 0.75
Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Med (2015) 0.75
Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Onco Targets Ther (2017) 0.75
Interleukin-35 on B cell and T cell induction and regulation. J Inflamm (Lond) (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med (1998) 2.69
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med (2000) 2.04
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Human allograft acceptance is associated with immune regulation. J Clin Invest (2000) 1.94
Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood (2009) 1.94
Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol (2009) 1.89
Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol (2003) 1.87
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res (2005) 1.64
Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol (2004) 1.63
Retracted Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol (2011) 1.56
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol (2005) 1.43
Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2010) 1.39
Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med (2004) 1.34
TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate (1997) 1.30
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol (2009) 1.26
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol (2007) 1.23
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys (2005) 1.22
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res (2008) 1.20
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest (2009) 1.19
Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol (1999) 1.16
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Antigen-specific TGF-β-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. J Immunol (2011) 1.13
Regulating the immune response to tumours. Adv Drug Deliv Rev (2006) 1.13
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help. Proc Natl Acad Sci U S A (1990) 1.09
Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol (2007) 1.06
Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol (2008) 1.01
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res (2010) 0.97
Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res (1999) 0.95
Human liver allograft acceptance and the "tolerance assay". II. Donor HLA-A, -B but not DR antigens are able to trigger regulation of DTH. Hum Immunol (2002) 0.92
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91
The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res (2008) 0.91
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother (2007) 0.89
Functional plasticity of antigen-specific regulatory T cells in context of tumor. J Immunol (2011) 0.88
Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res (2005) 0.87
Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS (2010) 0.86
Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J Urol (2012) 0.86
Human CD8+ T-regulatory cells with low-avidity T-cell receptor specific for minor histocompatibility antigens. Hum Immunol (2008) 0.85
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate (2011) 0.84
Increased peripheral CD4+CD25high Treg in prostate cancer patients is correlated with PSA. Saudi Med J (2011) 0.77
Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol (2010) 0.76
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol (2004) 10.60
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 3.75
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest (2007) 3.31
Generation of T-cell receptor retrogenic mice. Nat Protoc (2006) 3.05
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods (2006) 2.87
Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol (2005) 2.34
Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat Immunol (2008) 2.34
T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity (2009) 2.34
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther (2005) 2.31
The plasticity and stability of regulatory T cells. Nat Rev Immunol (2013) 2.15
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol (2004) 2.00
Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature (2013) 1.99
Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood (2009) 1.94
General nature of the STAT3-activated anti-inflammatory response. J Immunol (2006) 1.90
Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol (2009) 1.89
The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol (2003) 1.80
Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 1.79
Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant (2004) 1.77
Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol (2013) 1.74
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 1.66
The development and function of regulatory T cells. Cell Mol Life Sci (2009) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Developmental exposure to noninherited maternal antigens induces CD4+ T regulatory cells: relevance to mechanism of heart allograft tolerance. J Immunol (2007) 1.64
Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. Blood (2009) 1.63
Pretransplant immune regulation predicts allograft outcome: bidirectional regulation correlates with excellent renal transplant function in living-related donor-recipient pairs. Transplantation (2012) 1.63
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes (2008) 1.61
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Interleukin-35: odd one out or part of the family? Immunol Rev (2008) 1.60
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Retracted Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol (2011) 1.56
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol (2010) 1.50
In vitro Treg suppression assays. Methods Mol Biol (2011) 1.46
Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med (2008) 1.44
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol (2002) 1.43
Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol (2008) 1.42
Analysis of nondegradative protein ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin. Proc Natl Acad Sci U S A (2008) 1.42
Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol (2002) 1.41
Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol (2010) 1.35
Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med (2004) 1.34
Tolerance to noninherited maternal MHC antigens in mice. J Immunol (2003) 1.33
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Cutting edge: virus-specific CD4+ memory T cells in nonlymphoid tissues express a highly activated phenotype. J Immunol (2002) 1.28
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol (2011) 1.28
Once a Treg, always a Treg? Immunol Rev (2014) 1.27
Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb Protoc (2012) 1.26
Organization of proximal signal initiation at the TCR:CD3 complex. Immunol Rev (2009) 1.25
Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol (2007) 1.23
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Mol Ther (2005) 1.23
The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol (2002) 1.22
Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes (2012) 1.21
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res (2011) 1.19
Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J Immunol (2009) 1.17
Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. J Immunol (2004) 1.17
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
The CD3epsilon proline-rich sequence, and its interaction with Nck, is not required for T cell development and function. J Immunol (2005) 1.13
Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J Immunol (2004) 1.13
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Tonic ubiquitylation controls T-cell receptor:CD3 complex expression during T-cell development. EMBO J (2010) 1.11
An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol (2012) 1.10
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol (2010) 1.09
HLA class I noninherited maternal antigens in cord blood and breast milk. Hum Immunol (2004) 1.09
Tolerance to noninherited maternal antigens in mice and humans. Curr Opin Organ Transplant (2009) 1.09
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes (2012) 1.09
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol (2010) 1.07
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol (2007) 1.06
Human NKT cells promote monocyte differentiation into suppressive myeloid antigen-presenting cells. J Leukoc Biol (2009) 1.06
The proline-rich sequence of CD3epsilon as an amplifier of low-avidity TCR signaling. J Immunol (2008) 1.05
Chimerism, tolerance, and twins. Obstet Gynecol (2010) 1.05